Search
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnIt was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.
Remifentanil
go.drugbank.com/drugs/DB00899ApprovedInvestigationalRemifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: REMIFENTANILO 2MG POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE O INFUSION INTRAVENOSA, REMIFENTANILO 5MG POLVO POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE O INFUSIÓN INTRAVENOSA.Benralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigational[A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019] … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils
Alfuzosin
go.drugbank.com/drugs/DB00346Approved[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.
Synonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamideProducts: ALFUZOSIN RATIO UNO 10MGValine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%mRNA-1010
go.drugbank.com/drugs/DB22484ApprovedMFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza. … benefit to be confirmed in a postmarketing trial.
Iodine povacrylex
go.drugbank.com/drugs/DB09537ApprovedProlonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin. … DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. … [A6921] Ofatumumab was first approved by the FDA in 2009.
Gefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalActing in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Synonyms: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamineDexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions.